Published in Br J Cancer on February 01, 1986
Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg (2008) 2.27
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer (1986) 1.44
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer (1989) 1.18
Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9. Cell Mol Gastroenterol Hepatol (2016) 1.02
Human ductal adenocarcinomas of the pancreas express extracellular matrix proteins. Br J Cancer (1994) 0.95
CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer. Int J Mol Imaging (2011) 0.89
Enzyme-linked PNA lectin binding assay compared with CA19-9 and CEA radioimmunoassay as a diagnostic blood test for pancreatic cancer. Br J Cancer (1989) 0.84
A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts. Mol Imaging Biol (2014) 0.80
Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma. Br J Cancer (1991) 0.80
Expression of CA125 in pancreatic carcinoma and chronic pancreatitis. Br J Cancer (1988) 0.78
Oncofetal markers CA 19-9, CA 125 and SP1 in healthy children and in children with malignancy. Br J Cancer (1990) 0.78
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem (1983) 3.91
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res (1983) 3.15
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol (1984) 1.98
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol (1982) 1.76
Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases. Br J Cancer (1984) 1.56
Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer (1984) 1.42
Laboratory: The Cultivation of Endameba Gingivalis (Gros) from the Human Mouth. Am J Public Health Nations Health (1929) 1.33
Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma (1983) 1.18
Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest (1984) 1.18
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology (1999) 2.56
Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer (2007) 2.36
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. J Clin Invest (1999) 2.32
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res (1995) 2.31
The release of amino acids with proposed neurotransmitter function from the cuneate and gracile nuclei of the rat in vivo. Brain Res (1974) 2.24
Allograft response in vitro. Transplant Rev (1972) 2.20
Sequential appearance of fibronectin and collagen in experimental granulation tissue. Lab Invest (1980) 2.16
Hepatosplenic candidiasis in patients with acute leukemia: incidence and prognostic implications. Clin Infect Dis (1997) 2.08
Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut (2005) 2.07
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br J Cancer (1986) 1.91
Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer (2003) 1.86
Carcinoembryonic antigen in malignant and nonmalignant gynecologic tumors: circulating levels and tissue localization. Cancer (1978) 1.84
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol (2009) 1.78
The distribution and axonal transport of free amino acids and related compounds in the dorsal sensory neuron of the rat, as determined by the dansyl reaction. J Neurochem (1973) 1.70
Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem (1999) 1.52
Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol (2000) 1.51
Effective dose during screening monitored intussusception reduction. Clin Radiol (1993) 1.47
Absence of the major sialoglycoprotein in the membrane of human En(a--) erythrocytes and increased glycosylation of band 3. J Biol Chem (1976) 1.46
Proliferation of B and T cells in mixed lymphocyte cultures. J Exp Med (1973) 1.46
Effects of heavy drinking, binge drinking, and family history of alcoholism on regional brain metabolites. Alcohol Clin Exp Res (2004) 1.45
Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer (1986) 1.44
The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer (1994) 1.44
[Treatment of depression and cost efficiency. The cost of a tablet is a poor indicator seen from a socioeconomic perspective]. Lakartidningen (2000) 1.39
Stimulation of density-inhibited cell cultures by insulin. J Cell Physiol (1973) 1.37
CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res (2002) 1.36
Bmi-1 expression predicts prognosis in squamous cell carcinoma of the tongue. Br J Cancer (2010) 1.33
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 1.32
The transforming growth factor beta(1)-inducible transcription factor TIEG1, mediates apoptosis through oxidative stress. Hepatology (1999) 1.32
Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine. Eur J Pharmacol (1993) 1.30
Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9. Int J Cancer (1987) 1.30
Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer (1993) 1.28
Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer (1991) 1.25
Allograft immunity in vitro. VI. Autonomy of T lymphocytes in target cell destruction. Scand J Immunol (1973) 1.25
Neuraminidase stimulates division and sugar uptake in density-inhibited cell cultures. Nat New Biol (1972) 1.22
Presynaptic gamma-aminobutyric acid receptors in the rat anococcygeus muscle and their antagonism by 5-aminovaleric acid. Br J Pharmacol (1982) 1.22
Allergic rhinitis and the common cold--high cost to society. Allergy (2009) 1.22
Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol (2001) 1.22
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer (2013) 1.21
Separation of T and B lymphocytes by preparative cell electrophoresis. Eur J Immunol (1972) 1.19
Tissue expression of the tumour associated antigen CA242 in benign and malignant pancreatic lesions. A comparison with CA 50 and CA 19-9. Br J Cancer (1989) 1.18
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol (2006) 1.14
Purification and analysis of mitochondrial membrane proteins on nondenaturing gradient polyacrylamide gels. Anal Biochem (1986) 1.14
Prenatal diagnosis of congenital nephrosis in 23 high-risk families. Am J Dis Child (1978) 1.13
Reliability of radiographs in defining union of internally fixed fractures. Injury (2004) 1.13
Elevation of free beta subunit of human choriogonadotropin and core beta fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease. Cancer Res (1992) 1.11
Fractionation of mouse T and B lymphocytes by preparative cell electrophoresis. Efficiency of the method. Cell Immunol (1973) 1.10
Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience (1993) 1.10
Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br J Cancer (2004) 1.09
Demonstration and biochemical characterisation of rat brain NADPH-dependent diaphorase. J Neurochem (1988) 1.09
Transfilter induction of kidney tubles: correlation with cytoplasmic penetration into nucleopore filters. J Embryol Exp Morphol (1974) 1.09
Prostaglandin and noradrenaline interactions in rat brain synaptosomes [proceedings]. Br J Pharmacol (1979) 1.09
Does the type of flooring affect the risk of hip fracture? Age Ageing (2004) 1.09
Development of cytochrome b and an active oxidase system in association with maturation of a human promyelocytic (HL-60) cell line. J Cell Biol (1982) 1.08
European guidelines for quality assurance in the surgical management of mammographically detected lesions. European Breast Cancer Working Group. Ann Chir Gynaecol (1998) 1.07
Activation of human monocytes occurs on cross-linking monocytic antigens to an Fc receptor. J Immunol (1989) 1.06
Tumour-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer (1986) 1.06
17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study. Genes Chromosomes Cancer (1997) 1.06
Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer (2011) 1.06
The uptake and release of [3-H]-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthlane (ADTN) by striatal nerve terminals. Br J Pharmacol (1978) 1.06
Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer (2001) 1.05
Epithelial syndecan-1 expression is associated with stage and grade in colorectal cancer. Oncology (2005) 1.03
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer (1994) 1.03
Cystatin A expression reduces bile salt-induced apoptosis in a rat hepatoma cell line. Am J Physiol (1998) 1.02
Carcinoma of the stomach and its heredity in young patients. Scand J Gastroenterol (1988) 1.02
Thymus-dependent and thymus-independent lymphocyte separation: relation to exposed sialic acid on cell surface. Science (1972) 1.01
Presence of high-level DNA copy number gains in gastric carcinoma and severely dysplastic adenomas but not in moderately dysplastic adenomas. Cancer Genet Cytogenet (1998) 1.01
Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res (1996) 1.01
Childhood cancer and paternal exposure to ionizing radiation: preliminary findings from the Oxford Survey of Childhood Cancers. Am J Ind Med (1993) 1.01
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer? Br J Cancer (1995) 1.01
Rat brain NADPH-dependent diaphorase. A possible relationship to cytochrome P450 reductase. Biochem Pharmacol (1988) 1.00
Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer (1998) 1.00
Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer (1998) 1.00
Agonist-induced internalization of the metabotropic glutamate receptor 1a is arrestin- and dynamin-dependent. J Neurochem (2001) 0.99
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer (2011) 0.99
High affinity l-[3h]glutamate binding to postsynaptic receptor sites on rat cerebellar membranes. J Neurochem (1978) 0.99
Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA. Br J Cancer (1987) 0.98
Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol (1992) 0.98
Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum. J Neurochem (1985) 0.98
Mechanism of human monocyte activation via the 40-kDa Fc receptor for IgG. J Immunol (1988) 0.98